TP53 and myelodysplastic syndrome: A study by Wong et al. is one of the first to demonstrate this; They identified four cases of therapy related acute myeloid leukaemia (t-AML) and myelodysplastic syndrome (t-MDS) whereby TP53 mutations were detected in peripheral blood samples or bone marrow 3–6 years before tMN diagnosis [58].